BSH 2023 | Treatment avenues for patients with R/R FLT3-mutated AML: optimizing FLT3 inhibitors
Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the use of FLT3 inhibitors to treat patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), highlighting the ADMIRAL trial (NCT02421939), which demonstrated improved outcomes in patients receiving gilteritinib compared with salvage chemotherapy. Prof. Vyas further notes a discussion at BSH 2023 which addressed the practicalities of identifying patients suited to FLT3 inhibitor therapy at relapse and the potential benefits of initiating therapy upon molecular relapse. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
